ArticleBMC microbiology2026
Analysis of virulence of the emerging opportunistic human pathogen Achromobacter in a zebrafish embryo model.
Article in BMC microbiology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
Abstract
backgroundAchromobacter spp. are emerging opportunistic pathogens of concern in people with cystic fibrosis (CF) and immunocompromised individuals. These bacteria are known for their intrinsic antibiotic resistance and ability to evade host immune defences. A more comprehensive understanding of the direct interaction between Achromobacter spp. and the host innate immune system is necessary for the development of effective intervention strategies. In this study, we used zebrafish embryos to investigate the pathogenic potential of a panel of clinical Achromobacter spp. isolates and analysed their interaction with the host innate immune system.
resultsSeven CF isolates previously shown to cause distinct levels of cytotoxicity in cell culture, and virulence and inflammation in Galleria mellonella larvae and mice, respectively, were analysed in a zebrafish embryo model. One strain caused significant host mortality (87.5%) in zebrafish embryos by 4 days post intravenous injection. Mortality was associated with a strong increase in bacterial load and increased pro-inflammatory cytokine gene expression. Three strains were moderately virulent and induced 8.4 to 12.5% host mortality, with surviving embryos having a constant bacterial load until 4 days post infection, indicating bacterial persistence. The remaining three isolates persisted, but caused less than 3% mortality, and were cleared by 27% of infected embryos, which was associated with minimal induction of pro-inflammatory gene expression at 1 day post infection. To elucidate the role of macrophages, macrophage-depleted embryos were compared with macrophage-proficient embryos after infection with the least virulent strain (0% mortality). The absence of macrophages led to a strong increase in bacterial load and 34% mortality within 4 days, demonstrating a significant role for macrophages in controlling bacterial growth and limiting infection severity. Real time analysis revealed, however, that some isolates were able to survive and replicate in macrophages, thereby contributing to either persistent or pro-inflammatory infection. These results demonstrated both host-detrimental and host-beneficial roles for macrophages during infection.
conclusionZebrafish embryos represent a valuable model for studying Achromobacter-host interactions during both persistent and acute infection, particularly to study the role of immune cells and obtain insights into host-pathogen interactions in real-time. The zebrafish infection model will be a helpful tool for the discovery antimicrobial strategies against Achromobacter spp. INFECTIONS:
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.